SCHEMBL4965075

SCHEMBL4965075

C[Si](C)(C)CCOCONC(=O)c1ncc2c(ccn2Cc2ccc(F)cc2)c1CCO

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.36
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
GAA P10253 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
EGLN1 Q9GZT9 2/20 0.33
CNR2 P34972 2/20 0.33
MMP13 P45452 1/20 0.33
GRIN2B Q13224 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90B1 P14625 1/20 0.33
PTGER4 P35408 1/20 0.33
DRD2 P14416 1/20 0.32
HTR6 P50406 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3495643 0.78 EGLN1 (0.43) MAOBLMNASMN1; SMN2CYP11B1CYP11B2
SCHEMBL3495191 0.76 MAOB (0.35) MAOBTP53RXFP1L3MBTL1POLB
SCHEMBL4965249 0.76 HSP90AA1 (0.34) MAOBLMNATP53RXFP1GAA
SCHEMBL4965256 0.76 HSP90AA1 (0.34) MAOBLMNATP53RXFP1GAA
SCHEMBL4807256 0.76 HDAC1 (0.44) MAOBCYP11B1CYP11B2CNR2MMP13
SCHEMBL3496597 0.72 CYP11B1 (0.46) MAOBLMNATP53SMN1; SMN2CYP11B1
SCHEMBL14533491 0.72 L3MBTL1 (0.43) MAOBLMNATP53RXFP1GAA
SCHEMBL4801391 0.72 HDAC6 (0.46) MAOBGAAL3MBTL1EGLN1CNR2
SCHEMBL3496747 0.72 CYP11B1 (0.42) MAOBLMNAGAAL3MBTL1POLB
SCHEMBL3494864 0.72 CNR2 (0.35) MAOBTP53L3MBTL1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1934220-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME Pfizer Products Incorporated (US) 2008-06-25 EP disclosed
US-20070099915-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC. 2007-05-03 US disclosed
US-20070099915-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC. 2007-05-03 US disclosed
US-20070099915-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC. 2007-05-03 US disclosed
WO-2007042883-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER PRODUCTS INC. (US) 2007-04-19 WO disclosed
WO-2007042883-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER PRODUCTS INC. (US) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099915-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME IMPDH1, INTS9, TYMP MAOB 979/4885LMNA 3259/4885TP53 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.